September, 2025
September 2025
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  
Steve Hahn Joins Nucleus RadioPharma as Chief Executive Officer
Sep 8, 2025, 15:06

Steve Hahn Joins Nucleus RadioPharma as Chief Executive Officer

Steve Hahn, Chief Executive Officer of Nucleus RadioPharma and Principal at Rubrum Advising, shared a post on LinkedIn:

“I’ve dedicated my career to improving patient care – as an oncologist, as Chief Medical Executive at MD Anderson Cancer Center, and as FDA Commissioner during one of the most challenging public health crises of our time.

At the FDA, I witnessed firsthand what’s possible when public and private sectors come together with urgency and focus. The rapid development and deployment of the COVID-19 vaccines showed that what many thought ‘impossible’ could in fact be achieved when incentives are aligned and barriers to collaboration fall away.

That experience has deeply influenced my next chapter.

I’m honored to join Nucleus RadioPharma, as CEO, where our mission is to fix one of the most overlooked bottlenecks in cancer care: Manufacturing and delivering precision radiopharmaceuticals at scale, particularly for the majority of patients who receive care in the community oncology setting.

Radiopharmaceuticals are among the most promising advances in oncology today, with the potential to treat millions of patients. But without the infrastructure to reliably produce and distribute them, too many people are left without access. At Nucleus, we’re building the first fully integrated platform to change that – ensuring the right treatment gets to the right patient at the right time.

I believe this is a once-in-a-generation opportunity to enable access to an impactful form of cancer treatment that leaves no one behind, and I’m grateful to Eclipse and the Mayo Clinic for their partnership in founding and backing Nucleus with the conviction this mission demands. Together, we can make what was once thought impossible, possible – and bring hope to millions of patients and families.

Eclipse has written more on this journey and the vision to accelerate development and expand access to precision cancer medicines.”

More posts on OncoDaily.